Bioventus BVS U.S. Segment — Adjusted selling expense

Similar metrics at other companies

XMTRUS — Segment Adjusted Operating Expense

$53.05M+17.7%

PPCU.S. — Selling, general and administrative expense

$109.65M+59.3%

VSTSUnited States — Selling, general and administrative expenses

$75.68M-29.9%

MURUnited States — Selling and general expenses

$5.5M+175%

FERGUnited States Segment — Cost of Product and Service Sold

$4.92B+3.0%

DNOWUS — Selling General And Administrative Expense

$200M+125%

Questions, answered.

What is Bioventus's U.S. segment — adjusted selling expense?

Bioventus (BVS) reported U.S. segment — adjusted selling expense of $38.24M in Q1 2026.

How has Bioventus's U.S. segment — adjusted selling expense changed year-over-year?

Bioventus's U.S. segment — adjusted selling expense increased by 10.2% year-over-year, from $34.72M to $38.24M.

What is the long-term trend for Bioventus's U.S. segment — adjusted selling expense?

Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted selling expense has grown at a 1.0% compound annual growth rate (CAGR), from $147.77M to $152.08M.

What does U.S. segment — adjusted selling expense mean?

This metric measures the adjusted costs incurred by the sales force to promote and distribute products within the U.S. market. It reflects the investment required to maintain customer relationships and drive product adoption among orthopedic physicians and surgical centers.